SRPT
Sarepta Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.27B
P/E Ratio
—
EPS
$-7.13
Beta
0.28
52W High
$64.80
52W Low
$10.42
50-Day MA
$19.54
200-Day MA
$19.70
Dividend Yield
—
Profit Margin
-32.50%
Forward P/E
5.68
PEG Ratio
159.25
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $2.20B |
| Gross Profit (TTM) | $-163.43M |
| EBITDA | $-613.25M |
| Operating Margin | -92.60% |
| Return on Equity | -53.50% |
| Return on Assets | -11.20% |
| Revenue/Share (TTM) | $21.96 |
| Book Value | $10.87 |
| Price-to-Book | 1.99 |
| Price-to-Sales (TTM) | 1.03 |
| EV/Revenue | 1.078 |
| EV/EBITDA | 86.30 |
| Quarterly Earnings Growth (YoY) | 2664.00% |
| Quarterly Revenue Growth (YoY) | -32.70% |
| Shares Outstanding | $105.57M |
| Float | $92.88M |
| % Insiders | 4.09% |
| % Institutions | 90.01% |
Historical Volatility
HV 10-Day
30.38%
HV 20-Day
42.22%
HV 30-Day
104.88%
HV 60-Day
87.89%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($21.78 target)
7
Buy13
Hold3
Sell2
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/2/2026